TORONTO, March 11, 2010 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into two definitive license agreements with University Health ...
Dr. Christopher Paige, VP Research at UHN stated "We are very pleased to have created this partnership with a vibrant Canadian biotechnology company like Trillium Therapeutics. It represents an excellent example of how Research Hospitals like UHN and ...
Their findings have been published in the journal Nature Immunology. The work has been carried out by a team at the MRC Toxicology Unit at the University of Leicester. Dr Melania Capasso, one of the authors of the study, described the findings as ...
Their findings have been published in the journal Nature Immunology . The work has been carried out by a team at the MRC Toxicology Unit at the University of Leicester. Dr Melania Capasso, one of the authors of the study, described the findings as ...